Literature DB >> 2833202

Identification of the pseudorabies virus glycoprotein gp50 as a major target of neutralizing antibodies.

M Eloit1, D Fargeaud, R L'Haridon, B Toma.   

Abstract

A total of 108 monoclonal antibodies specific for pseudorabies virus (PRV) were isolated in a cellular fusion, using spleen cells from mice which had been immunized with a live strain (Kojnok strain). Twelve of them neutralized the Kojnok strain in vitro in the absence of complement, as well as 28 virulent strains of various geographical origin and isolated from various animal species. All of the 12 clones were specific for glycoprotein gp50. Eighteen other clones with no neutralizing activity were studied: 11 reacted with glycoprotein GIII, 3 with glycoprotein GII, 3 with the glycoprotein gp63 and 1 with the glycoprotein GI. Transfer to mice of ascitic fluids corresponding to clones reacting with gp50 and GIII showed that some of them provided the mice with the ability of resisting to virulent challenge. Thus it appears that glycoproteins gp50 and GIII are major immunogens of the virion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2833202     DOI: 10.1007/BF01311022

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  18 in total

1.  Deletions in vaccine strains of pseudorabies virus and their effect on synthesis of glycoprotein gp63.

Authors:  E A Petrovskis; J G Timmins; T M Gierman; L E Post
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

2.  Demonstration of three major species of pseudorabies virus glycoproteins and identification of a disulfide-linked glycoprotein complex.

Authors:  N Lukàcs; H J Thiel; T C Mettenleiter; H J Rziha
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Monoclonal antibodies to the glycoprotein of vesicular stomatitis virus: comparative neutralizing activity.

Authors:  W A Volk; R M Synder; D C Benjamin; R R Wagner
Journal:  J Virol       Date:  1982-04       Impact factor: 5.103

5.  Characterization and mapping of a nonessential pseudorabies virus glycoprotein.

Authors:  M W Wathen; L M Wathen
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

6.  DNA sequence of the gene for pseudorabies virus gp50, a glycoprotein without N-linked glycosylation.

Authors:  E A Petrovskis; J G Timmins; M A Armentrout; C C Marchioli; R J Yancey; L E Post
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

7.  Use of lambda gt11 to isolate genes for two pseudorabies virus glycoproteins with homology to herpes simplex virus and varicella-zoster virus glycoproteins.

Authors:  E A Petrovskis; J G Timmins; L E Post
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

8.  Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection.

Authors:  J T Rector; R N Lausch; J E Oakes
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

9.  Construction of E. coli expression plasmid libraries: localization of a pseudorabies virus glycoprotein gene.

Authors:  A K Robbins; J H Weis; L W Enquist; R J Watson
Journal:  J Mol Appl Genet       Date:  1984

10.  Characterization of the envelope proteins of pseudorabies virus.

Authors:  H Hampl; T Ben-Porat; L Ehrlicher; K O Habermehl; A S Kaplan
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

View more
  18 in total

1.  Correlation between gI, gII, gIII, and gp 50 antibodies and virus excretion in vaccinated pigs infected with pseudorabies virus.

Authors:  M Eloit; P Vannier; E Hutet; A Fournier
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  Glycoprotein gI of pseudorabies virus promotes cell fusion and virus spread via direct cell-to-cell transmission.

Authors:  L Zsak; F Zuckermann; N Sugg; T Ben-Porat
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

Review 3.  Molecular biology of pseudorabies virus: impact on neurovirology and veterinary medicine.

Authors:  Lisa E Pomeranz; Ashley E Reynolds; Christoph J Hengartner
Journal:  Microbiol Mol Biol Rev       Date:  2005-09       Impact factor: 11.056

4.  Mapping and characterization of neutralizing epitopes of glycoproteins gIII and gp50 of the Indiana-Funkhauser strain of pseudorabies virus.

Authors:  N E Coe; W L Mengeling
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

5.  Identification of pseudorabies virus-exposed swine with a gI glycoprotein enzyme-linked immunosorbent assay.

Authors:  M W Mellencamp; N E Pfeiffer; B T Suiter; J R Harness; W H Beckenhauer
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

6.  Glycoprotein D-negative pseudorabies virus can spread transneuronally via direct neuron-to-neuron transmission in its natural host, the pig, but not after additional inactivation of gE or gI.

Authors:  W Mulder; J Pol; T Kimman; G Kok; J Priem; B Peeters
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

7.  Novel recombinant parapoxvirus vectors induce protective humoral and cellular immunity against lethal herpesvirus challenge infection in mice.

Authors:  Timo Fischer; Oliver Planz; Lothar Stitz; Hanns-Joachim Rziha
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  The pseudorabies virus homology of the herpes simplex virus UL21 gene product is a capsid protein which is involved in capsid maturation.

Authors:  N de Wind; F Wagenaar; J Pol; T Kimman; A Berns
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Pseudorabies virus glycoproteins gII and gp50 are essential for virus penetration.

Authors:  I Rauh; T C Mettenleiter
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

10.  Virus production and viral antigen expression in porcine blood monocytes inoculated with pseudorabies virus.

Authors:  H J Nauwynck; M B Pensaert
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.